Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Becotatug Vedotin Combined With Putlimab in Locally Advanced Head and Neck Squamous Cell Carcinoma
NCT07707167Phase 2Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- Aug 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
A Phase 2 trial of becotatug vedotin in head and neck squamous cell carcinoma (HNSCC), sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
becotatug vedotin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07707167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07707167.